Digital How to Stand Out in a Saturated Digital Market As oncologists are increasingly pressed for time and attention, it's more important than ever for pharmaceutical brands to make the most of their limited online engagement. On average, HCPs spend only 36 seconds
Conferences ASH'22: Showcasing cutting-edge approaches for treating Acute Myeloid Leukemia Abstracts for the American Society of Hematology’s (ASH) 64th Annual Meeting were released on November 3rd, in anticipation of opening remarks beginning in New Orleans on December 10. As the healthcare world
Conferences Novel approaches for treating Multiple Myeloma will be featured in ASH 2022 Abstracts for the American Society of Hematology’s (ASH) 64th Annual Meeting were released on November 3rd, in anticipation of opening remarks beginning in New Orleans on December 10. As the healthcare world
Conferences 3 Key Themes at ASN 2022 American Society of Nephrology (ASN), will hold it’s 2022 edition of kidney week conference in Orlando, Florida from November 3rd to November 6th. The conference is one of its kind and the
Oncology 2022 ASCO Annual Meeting: Major Scientific Progress Moves the Field of Oncology Beyond COVID A strong line up of potentially practice-changing presentations generated a great deal of excitement among attendees at ASCO#2022 – both those in person at the McCormick Convention Center and those attending virtually. Based
Conferences Recent Advances in Multiple Myeloma (ASH 2021) Data that was released during the American Society of Hematology (ASH) 2021 meeting represents significant progress in the field and will have a positive impact on patients’ lives. Below are a few of
Conferences New Data in Early Settings and the Continued Development of Immunotherapies Captured Attention during ASCO's 2021 Annual Meeting. Among clinical topics, new data in early settings and continued development of immunotherapies stood out to oncologists as areas that can change their practice in the immediate future.
Conferences Participant Highlights from AAAAI 2021 Among the specific topics commanding healthcare professionals' (HCP) attention were the potential for Sanofi’s Dupixent in eosinophilic esophagitis, Amgen’s tezepelumab in uncontrolled asthma, and Lilly’s Olumiant in atopic dermatitis.
